<DOC>
	<DOCNO>NCT00813813</DOCNO>
	<brief_summary>Study show effectiveness safety single injection rhGDF5 degenerate single spinal disc treat lumbar level degenerative disc disease</brief_summary>
	<brief_title>Intradiscal rhGDF-5 Phase I/II Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<criteria>1 . Persistent low back pain , least 3 month nonsurgical therapy , one symptomatic lumbar level ( L3/L4 L5/S1 ) confirm use standardize discography protocol 2 . Oswestry Disability Index 30 great 3 . Low back pain score great equal 4 cm measure VAS , Visit 1 baseline day treatment confirm eligibility prior administration 1 . Persons unable discogram , CT MRI 2 . Abnormal neurological exam baseline ( e.g. , radiculopathy ) 3 . Radicular pain 4 . Leak contrast agent discogram , epidural space ( include leak contrast agent along needle track ) 5 . MRI finding demonstrate following : 路 Suspected disc appear normal路 &gt; 50 % decrease disc height路 Modic change , and/or路 Presence osteophytes significant facet arthrosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>